Company Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Country | United States |
Founded | 2004 |
IPO Date | Jul 25, 2018 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 142 |
CEO | Daniel Barber |
Contact Details
Address: 30 Technology Drive Warren, New Jersey 07059 United States | |
Phone | 908 941 1900 |
Website | aquestive.com |
Stock Details
Ticker Symbol | AQST |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001398733 |
CUSIP Number | 03843E104 |
ISIN Number | US03843E1047 |
Employer ID | 20-8623253 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Daniel Barber | Chief Executive Officer, President and Director |
A. Ernest Toth Jr. | Chief Financial Officer |
Lori J. Braender BSBA, Esq., J.D. | Chief Legal Officer, Chief Compliance Officer &Secretary |
Cassie Jung | Chief Operating Officer |
Dr. Stephen Wargacki Ph.D. | Chief Science Officer |
Sherry Korczynski | Senior Vice President of Sales and Marketing |
Peter E. Boyd | Senior Vice President of Information Technology and Human Resources |
Dr. Gary H. Slatko M.D., MBA | Chief Medical Officer |
Dr. Carl N. Kraus M.D. | Chief Medical Officer |
Robert Charles Arnold | Vice President of Finance, Controller and Assistant Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 1, 2025 | 8-K | Current Report |
Mar 10, 2025 | 8-K | Current Report |
Mar 5, 2025 | 10-K | Annual Report |
Mar 5, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 13, 2025 | SCHEDULE 13G/A | Filing |
Feb 12, 2025 | 8-K | Current Report |
Jan 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Jan 13, 2025 | 8-K | Current Report |
Dec 19, 2024 | 8-K | Current Report |